The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.
A collaboration between data scientists, clinical researchers, and community opticians in the UK is hoping to develop an ...
Hosted on MSN45m
FDA Clears Spravato For Monotherapy Depression TreatmentsThe Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
Cervical cancer is often highly treatable, with a five-year relative survival rate of 91% for localised, early-stage disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback